Day: April 2, 2022

Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with sotagliflozin treatment as compared to placebo THE WOODLANDS, Texas, April 02, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22). The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo. Treatment with sotagliflozin resulted in a significant reduction in major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal...

Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with DisopyramideREDWOOD-HCM Cohort 3 REDWOOD-HCM Cohort 3: evidence for clinical efficacy of aficamten patients with obstructive HCM and HF symptoms refractory to maximal medical therapy, including disopyramideSOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), were presented in a Moderated Poster Session by Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease,...

EVLI PLC STOCK EXCHANGE RELEASE 2 APRIL 2022 AT 4.00 PM. EET NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, NEW ZEALAND, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. SEE “IMPORTANT NOTICE” BELOW. Evli Bank Plc and Fellow Finance Plc announced on July 14, 2021 that they have agreed in a combination agreement of an arrangement whereby Evli Bank will demerge through a partial demerger into a new asset management group Evli Plc (“Evli”) (the “Demerger”) that will be listed and a company that will carry...

Will Look to Advance its Psychedelic Based Formulations VANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) through a research arrangement with Neuro-Zone Srl, (“Neuro-Zone”) based in Bresso, Italy, has achieved positive results from its in vitro biological assay (“bioassay”) development studies (“bioassay studies”); furthering the Company’s patent pending psychedelic bioactive compounds that could lead to groundbreaking drug formulations for Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Major Depressive Disorder (Depression) and Stroke, (collectively “targeted diseases” or “neurological indications”). Bioassay studies are...

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) — Kayne Anderson NextGen Energy & Infrastructure, Inc. (the “Fund”) (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of March 31, 2022. As of March 31, 2022, the Fund’s net assets were $500.0 million and its net asset value per share was $10.59. As of March 31, 2022, the Fund’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 526% and the Fund’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 397%.Kayne Anderson NextGen Energy & Infrastructure, Inc.Statement of Assets and LiabilitiesMarch 31, 2022(Unaudited)    (in...

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of March 31, 2022. As of March 31, 2022, the Company’s net assets were $1.5 billion, and its net asset value per share was $10.83. As of March 31, 2022, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 501% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 398%.Kayne Anderson Energy Infrastructure Fund, Inc.Statement of Assets and LiabilitiesMarch 31, 2022(Unaudited)    (in...

BRISBANE, Australia, April 01, 2022 (GLOBE NEWSWIRE) — Allkem Limited (ASX|TSX: “AKE”, the “Company”) provides an update on expected June quarter pricing for lithium carbonate and spodumene products. Lithium carbonate Strong market conditions continue to positively impact the price received for lithium carbonate from the Olaroz Lithium Facility. The June quarter FY22 average price received for lithium carbonate is expected to be approximately US$35,000/t FOB1 on sales of approximately 3,500 tonnes. The preliminary March quarter FY22 sales price was approximately US$27,236/t FOB, 9% higher than the previous guidance. Spodumene Similarly strong conditions in the spodumene market are supporting advanced discussions for spodumene concentrate pricing in the June quarter of approximately US$5,000/t SC6% CIF on sales of approximately...